
Exhibit 10.5

Certain identified information has been  {E1 excluded}  because it is both not material and would likely  {E2 cause}  competitive {E150 harm} if publicly  {E3 disclosed}  . COMMERCIALIZATION AND LICENSE AGREEMENT

This Commercialization and License Agreement (this "Agreement") is  {E4 made}  effective as of  December 17, 2019  (the "Effective  Date  ") by and between Vyera Pharmaceuticals, LLC, a Delaware limited liability company ("Vyera"), and CytoDyn Inc., a Delaware corporation ("CytoDyn"). CytoDyn and Vyera are sometimes  {E5 referred}  to herein individually as a "Party" and collectively as the "Parties."

RECITALS

WHEREAS, Vyera is a pharmaceutical company  {E6 engaged}  in the {E151 commercialization} of products useful in the {E152 amelioration}, {E153 treatment} or {E154 prevention} of certain human diseases and conditions. WHEREAS, CytoDyn has  {E7 developed}  leronlimab (PRO 140), an anti-CCR5 humanized monoclonal antibody and is  {E8 pursuing}  the clinical {E155 development} of its PRO 140 drug candidate for the {E156 treatment} of multi-drug resistant Human Immunodeficiency Virus ("HIV") infection, as well as related HIV infection indications. WHEREAS, the Parties  {E9 desire}  that, upon regulatory {E157 approval} of PRO 140 for the Initial Indication (as  {E10 defined}  below), Vyera will Commercialize (as  {E11 defined}  below) Licensed Products (as  {E12 defined}  below) in the {E269 Field} (as  {E13 defined}  below) in the Territory (as  {E14 defined}  below), all in accordance with the terms and conditions of this Agreement. NOW, THEREFORE, in consideration of the foregoing and the premises and conditions set forth herein, the Parties  {E15 agree}  as  follows  :

ARTICLE 1 DEFINITIONS

1.1 "AAA" has the meaning set forth in Section 12.3(a). 1.2 "AAI Agreement" has the meaning set forth in Section 9.2(o). 1.3 "Affiliate" means, with respect to a particular Party, a Person that  {E16 controls}  , is  {E17 controlled}  by or is under common control with such Party. For the purposes of this definition, the word "control" ( {E18 including}  , with correlative meaning, the terms " {E19 controlled}  by" or "under the common control with") means the actual power, either directly or indirectly through one (1) or more intermediaries, to  {E20 direct}  or  {E21 cause}  the direction of the {E158 management} and policies of such entity, whether by the ownership of fifty percent (50%) or more of the voting stock of such entity, by contract or otherwise. 1.4 "AGC Agreement" has the meaning set forth in Section 9.2(o). 1.5 "Agreement" has the meaning set forth in the introductory paragraph. 1.6 "Alliance Manager" means, with respect to each Party, the person  {E22 appointed}  by such Party from within its organization to  {E23 coordinate}  and  {E24 facilitate}  the {E159 communication}, {E160 interaction} and {E161 cooperation} of the Parties pursuant to this Agreement. The Alliance Managers shall be the primary contacts between the Parties with respect to the {E162 activities}  {E25 conducted}  pursuant to this Agreement. 1.7 "Annual WAC" means the  annual  wholesale acquisition cost for the Licensed Product. Source: CYTODYN INC., 10-Q,  1/9/2020 





1.8 "API" means an active pharmaceutical ingredient, whether  {E26 produced}  from a  {E27 living}  organism or through synthetic process (i.e., any substance  {E28 intended}  to be  {E29 used}  in the {E163 manufacture} of a drug product and that is  {E30 intended}  to  {E31 furnish}  pharmacological {E164 activity} in the {E165 cure}, {E166 treatment} or {E167 prevention} of disease). 1.9 "Applicable Law" means all applicable statutes, ordinances, regulations, rules, or orders of any kind whatsoever of any Governmental Authority,  {E32 including}  , without limitation, the FDCA, Prescription Drug Marketing Act, the Generic Drug Enforcement Act of  1992  (21 U.S.C. Â§335a et seq.), U.S. Patent Act (35 U.S.C. Â§1 et seq.), Federal Civil False Claims Act (31 U.S.C. Â§3729 et seq.), and Anti-Kickback Statute (42 U.S.C. Â§1320a-7b et seq.), all as  {E33 amended}  from time to time, together with any rules, regulations, and compliance guidance  {E34 promulgated}  thereunder. 1.10 "Arbitration {E168 Request}" has the meaning set forth in Section 12.3(b). 1.11 "Bankruptcy Laws" has the meaning set forth in Section 11.6(b). 1.12 "Biosimilar Competitor" means, with respect to the Licensed Product, a drug or biological product that has been  {E35 determined}  by the FDA to be therapeutically equivalent to the Licensed Product, such that it may be  {E36 substituted}  by a pharmacist for the Licensed Product in the Field in the Territory without the need for such pharmacist to  {E37 seek}  {E169 authorization} from the physician that  {E38 prescribed}  the Licensed Product. 1.13 "Biosimilar Entry  Date  " means the first  day  of the first Calendar Quarter that  {E39 occurs}  after Biosimilar Competitor(s) have  {E40 achieved}  at least [***] in the Field in the Territory. 1.14 "BLA" means a Biologics License Application (as  {E41 defined}  in the FDCA),  {E42 including}  all supplements, amendments, variations, extensions and renewals thereof. 1.15 "Breaching Party" has the meaning set forth in Section 11.4. 1.16 "Business Day" means  a day  other than  Saturday ,  Sunday  or any other  day  on which commercial banks  {E43 located}  in the State of New York or the State of Washington, U.S., are  {E44 authorized}  or  {E45 obligated}  by Applicable Law to  {E46 close}  . 1.17 "Calendar Quarter" means the respective periods of three (3) consecutive calendar months  {E47 ending}  on  March 31 ,  June 30 ,  September 30  and  December 31 ;  {E48 provided}  , however, that (a) the first Calendar Quarter of the  Term  shall  {E49 extend}  from the Effective  Date  to the end of the first complete Calendar Quarter thereafter; and (b) the last Calendar Quarter of the  Term  shall  {E50 end}  upon the {E170 expiration} or {E171 termination} of this Agreement. 1.18 "Calendar Year" means  the twelve-   month  period {E54 ending}  on  December 31 ;  {E52 provided}  , however, that (a) the first Calendar Year of the  Term  shall  {E53 begin}  on the Effective  Date  and  {E54 end}  on  December 31, 2019 ; and (b) the last Calendar Year of the  Term  shall  {E55 end}  on the effective  date  of {E172 expiration} or {E173 termination} of this Agreement. 1.19 "{E174 Change} of Control" means, with respect to Vyera, (a) the {E175 sale} of all or substantially all of its assets; (b) any {E176 merger}, {E177 consolidation} or {E178 acquisition} of Vyera, by or into another Person; and/or (c) any {E179 change} in the ownership of more than fifty percent (50%) of the voting capital stock of Vyera or its direct or indirect parent entities, other than: (i) {E180 transactions}  {E56 involving}  solely Vyera (or an Affiliate, as applicable) and/or one or more Affiliates, on the one hand, and one or more of Vyera's (or an Affiliate's, as applicable) Affiliates, on the other hand, and/or (ii) {E181 transactions} in which the stockholders of Vyera (or an Affiliate, as applicable) immediately prior to such {E182 transaction}  {E57 hold}  at least fifty percent (50%) of the  {E58 voting}  power of the  {E59 surviving}  company or ultimate parent company of the  {E60 surviving}  company; in each of clauses (a)-(c), in one or more related {E183 transactions}. Source: CYTODYN INC., 10-Q,  1/9/2020 





1.20 "{E184 Claim}" has the meaning set forth in Section 13.1. 1.21 "Clinical {E185 Trial}" means any human clinical {E186 study} or {E187 trial} of a Licensed Product in the Field in the Territory. 1.22 "Combination Product" means a product that is  {E61 Commercialized}  by Vyera and/or its Affiliates under this Agreement and that  {E62 comprises}  ,  {E63 consists}  of, or  {E64 incorporates}  two or more APIs (whether  {E65 administered}  together or separately), which  {E66 includes}  leronlimab as one of the APIs together with one or more additional APIs that: (a) are not leronlimab; and (b) are not proprietary to CytoDyn, regardless of the {E189 formulation} or mode of {E188 administration} of such Combination Product. For the sake of clarity, a Combination Product is a Licensed Product. 1.23 "Commercial {E67 Failure}" means that Vyera  {E67 fails}  to  {E68 achieve}  aggregate [***]. 1.24 "{E197 Commercialization}" means any and all pre- launch  , launch and post-launch {E197 activities}  {E69 related}  to the {E193 marketing},  {E70 promoting}  ,  {E71 distributing}  (to Third Parties),  {E72 offering}  for sale and  {E73 selling}  a Licensed Product in the Field in the Territory. For clarity, {E197 Commercialization}  does  not  {E74 include}  {E195 Development} and/or {E196 Manufacturing} of a Licensed Product. When  {E75 used}  as a verb, "Commercialize" means to  {E76 engage}  in {E197 Commercialization}. 1.25 "Commercialization Plan" has the meaning set forth in Section 5.2. 1.26 "Commercially Reasonable {E198 Efforts}" means: (a) with respect to the {E199 efforts} to be  {E77 expended}  , or considerations to be  {E78 undertaken}  , by a Party or its Affiliate with respect to any objective, {E203 activity} or {E204 decision} to be  {E79 undertaken}  hereunder, reasonable, good faith {E202 efforts} to  {E80 accomplish}  such objective, {E203 activity} or {E204 decision} as such Party would normally  {E81 use}  to  {E82 accomplish}  a similar objective, {E205 activity} or {E206 decision} under similar circumstances; and (b) with respect to {E207 Development} and {E208 Commercialization} of any Licensed Product for any indication by a Party, {E210 efforts} and resources consistent with those {E209 efforts} and resources commonly  {E83 used}  by a similarly  {E84 situated}  biotechnology company with respect to a product  {E85 owned}  by it or to which it has similar rights, which product is at a similar stage in its {E211 development} or product {E212 life} and is of similar market potential  {E86 taking}  into account (i) the patent and other proprietary position of the Licensed Product and (ii) the  {E87 anticipated}  profitability of the Licensed Product. 1.27 "Competitive Product" means any product for the {E213 treatment} or {E214 prevention} of [***],  leronlimab  that is not a Licensed Product. 1.28 "Confidential Information" means, subject to Article 10, all non-public or proprietary information not otherwise  {E88 included}  in Know-How  {E89 disclosed}  by either Party to the other Party in connection with the {E215 activities}  {E90 contemplated}  by this Agreement, which may  {E91 include}  ideas, {E216 inventions}, {E217 discoveries}, concepts, compounds, compositions, {E218 formulations}, formulas, {E219 practices}, procedures, processes, methods, knowledge, know-how, trade secrets, technology, inventories, machines, techniques, {E220 development}, designs, drawings, computer programs, knowledge, skill, {E221 experience}, documents, apparatus, results, clinical and regulatory strategies, Regulatory Documentation, and {E222 submissions}  {E92 pertaining}  to, or  {E93 made}  in association with, {E223 filings} with any Governmental Authority, data,  {E94 including}  pharmacological, toxicological and clinical data, analytical and quality control data,  {E95 manufacturing}  data and descriptions, patent and legal data, market data, financial data or descriptions, devices, assays, chemical formulations, specifications, material, product samples and other samples, physical, chemical and biological materials and compounds and information  {E96 related}  to such materials and compounds, and any {E224 modifications}, {E225 improvements}, designs, and recipes without regard as to whether any of the foregoing is  {E97 marked}  "confidential" or "proprietary," or  {E98 disclosed}  in oral,  {E99 written}  , graphic, or electronic form. Confidential Information shall  {E100 include}  the terms and conditions of this Agreement. Source: CYTODYN INC., 10-Q,  1/9/2020 





1.29 "Control" or " {E101 Controlled}  " means, with respect to any Know-How, Patent or other intellectual property right, possession ( {E102 including}  ownership) by a Party,  {E103 including}  its Affiliates, of the ability (without  {E104 taking}  into account any rights  {E105 granted}  by a Party to the other Party under the terms of this Agreement) to  {E106 grant}  access, a license or a sublicense to such  Know  -How, Patent or other intellectual property right without  {E107 violating}  the terms of any agreement or other arrangement with, or  {E108 necessitating}  the {E226 consent} of, any Third Party, at such time that the Party would be first  {E109 required}  under this Agreement to  {E110 grant}  the other Party such access, license or sublicense. 1.30 "Cost of Goods" means the amount  {E111 paid}  to CytoDyn by Vyera for the {E227 supply} of Licensed Products under the Supply Agreement (net of any mark-up  {E112 applied}  under the Supply Agreement). The Cost of Goods shall be the Cost of {E228 Manufacture} of Licensed Products  {E228 manufactured}  by CytoDyn (if applicable) or the amount actually  {E114 paid}  by CytoDyn to a Third Party for the {E229 Manufacture} and {E230 supply} of such Licensed Products. 1.31 "Cost of {E231 Manufacture}" [***]. 1.32 "Cover", " Covering  " or " {E115 Covered}  " means, with respect to a product, technology, process or method, that, in the absence of ownership of, or a license  {E116 granted}  under, a Valid {E234 Claim}, the {E232 practice} or {E233 Commercialization} of such product, technology, process or method would  {E117 infringe}  such Valid {E234 Claim} (or, in the case of a Valid {E237 Claim} that has not yet  {E118 issued}  , would  {E119 infringe}  such Valid {E237 Claim} if it were to  {E120 issue}  in its then  current  form or in a substantially similar version). 1.33 "Cure Period" has the meaning set forth in Section 11.4. 1.34 "CytoDyn" has the meaning set forth in the introductory paragraph. 1.35 "CytoDyn Indemnitee" has the meaning set forth in Section 13.1. 1.36 "CytoDyn Know-How" means any and all  Know  -How  {E121 Controlled}  by CytoDyn either or both as of the Effective  Date  or during the  Term  that is necessary or useful to Commercialize any Licensed Product in the Field in the Territory. 1.37 "CytoDyn Patents" means any and all Patents  {E122 Controlled}  by CytoDyn either or both as of the Effective  Date  or during the  Term  that  {E123 claim}  any CytoDyn Know-How or Inventions. The CytoDyn Patents as of the Effective  Date   {E124 include}  those set forth on Attachment A. CytoDyn may  {E125 update}  Attachment A from time to time to  {E126 remove}  reference to  {E127 expired}  Patents and to  {E128 include}  reference to additional Patents. 1.38 "CytoDyn Reserved {E238 Dispute}" has the meaning set forth in Section 12.4. 1.39 " {E129 Develop}  " or "{E254 Development}" means all {E240 research} and non-clinical and clinical drug development {E241 activities},  {E130 including}  toxicology, pharmacology, and other non-clinical {E242 efforts}, statistical {E243 analysis}, formulation {E244 development}, delivery system {E245 development}, the {E246 performance} of Clinical {E247 Trials},  {E131 including}  the {E248 Manufacturing}, as applicable, of the Licensed Product for {E249 use} in {E250 research} and Clinical {E251 Trials}, or other {E252 activities} reasonably necessary in order to  {E132 obtain}  and  {E133 maintain}  Regulatory {E253 Approval} of Licensed Products in the Field in the Territory. When  {E134 used}  as a verb, " {E135 Develop}  " {E149 means} to  {E136 engage}  in Development {E254 activities}. Source: CYTODYN INC., 10-Q,  1/9/2020 





1.40 "Development Plan" means the Development Plan  {E137 attached}  hereto as Attachment B, as it may be  {E138 amended}  in accordance with Section 4.3. 1.41 "Disclosing Party" has the meaning set forth in Section 10.1. 1.42 "Disposition Period" has the meaning set forth in Section 2.6. 1.43 "{E255 Dispute}" has the meaning set forth in Section 12.1. 1.44 "Effective  Date  " has the meaning set forth in the introductory paragraph. 1.45 "Equity Investment" has the meaning set forth in Section 8.13. 1.46 "Existing Licenses" has the meaning set forth in Section 9.2(b). 1.47 "FDA" means the U.S. Food and Drug Administration and any successor agency(ies) or authority  {E139 having}  substantially the same function. 1.48 "FDCA" means the United States Federal Food, Drug and Cosmetic Act of  1938  (21 U.S.C. Â§301 et seq.) and applicable regulations  {E140 promulgated}  thereunder, as  {E141 amended}  from time to time. 1.49 "{E256 Field}" means the {E256 treatment} of HIV in humans. 1.50 "Financial Statements" means (a) the  {E142 audited}  consolidated balance sheet of Vyera's parent company, Phoenixus AG and its subsidiaries, for the fiscal  year   {E144 ended}   December 31, 2018 , and the related consolidated statement of {E258 operations}, shareholders' equity and cash flows for the fiscal  year  then  {E144 ended}  , and (b) the unaudited consolidated balance sheet of Phoenixus AG for the eight (8) months  {E146 ended}   August 31, 2019 , and the related consolidated profit and loss statements for the eight (8) months then  {E146 ended}  . 1.51 "First Commercial {E260 Sale}" means, with respect to a Licensed Product, the first {E260 sale} of such Licensed Product to a Third Party by Vyera or its Affiliates after Regulatory {E261 Approval} of such Licensed Product has been  {E147 obtained}  . {E262 Sales} for test {E265 marketing}, sampling and promotional {E263 uses}, compassionate or similar {E264 use} shall not  {E148 constitute}  a First Commercial {E266 Sale} unless such {E267 sale} results in a Net {E268 Sale}. 1.52 [***].




